← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rhythm Pharmaceuticals, Inc.
Boston, MA
$999,353
Total funding
1
Grants
Funding over time
peak $396.3K · FY2015–17$500K$375K$250K$125K$0
'15
'16
'17
Funding mix
By agency
FDA$999,353 · 1
By mechanism
R01$999,353 · 1
Investigators at Rhythm Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of Prader-Willi syndrome$396,259
R01 · FY2015 · FD
Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of Prader-Willi syndrome$392,688
R01 · FY2016 · FD
Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of Prader-Willi syndrome$210,406
R01 · FY2017 · FD